{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-21-000106","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.026551+00:00","generated_at":"2026-06-28T13:46:03.072965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Penumbra Q3 revenue $190.1M (+26%), swings to operating profit; raises FY guidance","bullets":["Revenue $190.1M, +25.8% YoY (+25.6% constant currency); US 71%, international 29%.","Vascular segment $105.5M (+40.3%); Neuro segment $84.7M (+11.5%).","Gross margin 63.1% vs 60.2%; operating income $8.8M vs loss of $20.2M a year ago.","Full-year 2021 revenue guidance raised to $735M-$740M from prior $720M-$730M.","R&D expense fell to $16.7M from $34.9M; SG&A rose to $94.4M from $76.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-21-000106","json":"https://secwatch.observer/filing/0001321732-21-000106.json","markdown":"https://secwatch.observer/filing/0001321732-21-000106.md","text":"https://secwatch.observer/filing/0001321732-21-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173221000106/0001321732-21-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173221000106/pen-20211103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:46:03.072965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}